BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25336382)

  • 1. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations.
    Iuchi T; Shingyoji M; Itakura M; Yokoi S; Moriya Y; Tamura H; Yoshida Y; Ashinuma H; Kawasaki K; Hasegawa Y; Sakaida T; Iizasa T
    Int J Clin Oncol; 2015 Aug; 20(4):674-9. PubMed ID: 25336382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    Wang J; Liu Z; Pang Q; Zhang T; Chen X; Er P; Wang Y; Wang P; Wang J
    BMC Cancer; 2020 Sep; 20(1):837. PubMed ID: 32883221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
    Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
    Rangachari D; Yamaguchi N; VanderLaan PA; Folch E; Mahadevan A; Floyd SR; Uhlmann EJ; Wong ET; Dahlberg SE; Huberman MS; Costa DB
    Lung Cancer; 2015 Apr; 88(1):108-11. PubMed ID: 25682925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.
    Ge M; Zhuang Y; Zhou X; Huang R; Liang X; Zhan Q
    J Neurooncol; 2017 Nov; 135(2):413-418. PubMed ID: 28780743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
    Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.
    Luo D; Ye X; Hu Z; Peng K; Song Y; Yin X; Zhu G; Ji Q; Peng Y
    Tumour Biol; 2014 Mar; 35(3):2437-44. PubMed ID: 24197981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring
    Takamori S; Toyokawa G; Shimokawa M; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Mukae N; Hirai F; Tagawa T; Oda Y; Iwaki T; Iihara K; Honda H; Maehara Y
    Anticancer Res; 2018 Jun; 38(6):3731-3734. PubMed ID: 29848735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancer.
    Tozuka T; Noro R; Miyanaga A; Nakamichi S; Takeuchi S; Matsumoto M; Kubota K; Kasahara K; Seike M
    Cancer Med; 2023 Sep; 12(17):17731-17739. PubMed ID: 37691552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
    Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
    Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
    Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
    Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC.
    Tan L; Wu Y; Ma X; Yan Y; Shao S; Liu J; Ma H; Liu R; Chai L; Ren J
    Pathol Oncol Res; 2019 Apr; 25(2):791-799. PubMed ID: 30761450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors.
    Yun PJ; Wang GC; Chen YY; Wu TH; Huang HK; Lee SC; Chang H; Huang TW
    PLoS One; 2019; 14(5):e0215923. PubMed ID: 31048854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
    Furuya N; Ito K; Sakaguchi T; Hida N; Kakinuma K; Morikawa K; Inoue T; Komase Y; Hataji O; Mineshita M
    Oncology; 2020; 98(9):661-668. PubMed ID: 32464632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
    Villalva C; Duranton-Tanneur V; Guilloteau K; Burel-Vandenbos F; Wager M; Doyen J; Levillain PM; Fontaine D; Blons H; Pedeutour F; Karayan-Tapon L
    Cancer Med; 2013 Jun; 2(3):296-304. PubMed ID: 23930206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
    Ouyang W; Yu J; Zhou Y; Hu J; Huang Z; Zhang J; Xie C
    BMC Cancer; 2020 Jul; 20(1):699. PubMed ID: 32723319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases.
    Lee HL; Chung TS; Ting LL; Tsai JT; Chen SW; Chiou JF; Leung HW; Liu HE
    Radiat Oncol; 2012 Oct; 7():181. PubMed ID: 23110940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.